Immunovant lupus miss reads as isolated or a warning sign

Immunovant lupus miss reads as isolated or a warning sign

Following the September 23 announcement that IMVT-1402 failed its primary endpoint in a 57-patient cutaneous lupus erythematosus proof-of-concept trial, analysts are split between reading it as an isolated indication-specific miss versus a broader caution flag for the drug's autoimmune pipeline given the trial's small size.

The dominant readingSell-side analysts maintaining bullish ratings argue the failure is specific to cutaneous lupus and doesn't undercut IMVT-1402's prospects in Graves' disease or myasthenia gravis.

The pushbackSkeptics point to the trial's small 57-patient enrollment and note the numerical trends favoring the drug did not reach statistical significance, questioning whether the underlying biology is as clean as claimed.

Skepticalmoderate volume→ stableThat day's page →

• ↳Mood skeptical → cautious

Immunovant lupus miss reads as isolated or a warning sign

New that dayDetailed trial mechanics have since surfaced showing numerical trends favored the drug on several secondary measures and that deeper IgG reductions tracked with better responses, giving bulls more specific talking points than before.

Following the announcement that IMVT-1402 failed its Week 12 primary endpoint in a 57-patient cutaneous lupus erythematosus proof-of-concept trial, commentary is split between framing it as the expected loss of the portfolio's lowest-conviction indication versus a cautionary signal ahead of the more consequential difficult-to-treat rheumatoid arthritis readout.

The dominant readingBulls argue cutaneous lupus was always described as the long-shot indication among Immunovant's six-trial portfolio, so the miss changes little about the more advanced Graves' disease and myasthenia gravis programs.

The pushbackBears note this was the first randomized, placebo-controlled efficacy readout disclosed for IMVT-1402 across any indication, and that it not clearing the bar raises the stakes for the upcoming difficult-to-treat rheumatoid arthritis data.

Cautiousmoderate volume→ stableThat day's page →